Astrazeneca’s Calquence-based regimens approved for patients with chronic lymphocytic leukaemia in the 1st-line setting

AstraZeneca’s Calquence in combination with venetoclax has been approved in the EU for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

Note that CLL is the most common type of leukaemia in adults with an estimated 27,000 people were diagnosed with CLL in the UK, France, Germany and Spain.

Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany and investigator for the AMPLIFY trial, said: “For patients diagnosed with chronic lymphocytic leukaemia, this approval provides a new option in the first-line setting that may help to minimize long-term side effects and reduce drug resistance as they may occur with continuous treatment. A fixed-duration regimen is appealing to patients and helps with adherence during the treatment period.”

Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “Today’s approval brings a new fixed-duration treatment option to patients with previously untreated chronic lymphocytic leukaemia across Europe. Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor approved in the EU and provides patients and their physicians more flexibility in managing this incurable blood cancer.”

 

---

---

Related Topics and Keywords

AstraZeneca, calquence, chronic lymphocytic leukaemia